StockNews.com Begins Coverage on Chimerix (NASDAQ:CMRX)

StockNews.com started coverage on shares of Chimerix (NASDAQ:CMRX - Free Report) in a research note issued to investors on Sunday morning. The brokerage issued a hold rating on the biopharmaceutical company's stock.

A number of other research analysts have also commented on CMRX. HC Wainwright restated a "neutral" rating and set a $8.55 price target (down from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th. Jefferies Financial Group reissued a "hold" rating and set a $8.50 price objective (down previously from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th. Finally, Wedbush restated a "neutral" rating and issued a $8.55 target price (up from $7.00) on shares of Chimerix in a research note on Wednesday, March 5th.

Chimerix Trading Up 0.1 %

Shares of NASDAQ CMRX traded up $0.01 during mid-day trading on Friday, hitting $8.52. The company had a trading volume of 1,093,962 shares, compared to its average volume of 2,100,240. Chimerix has a 1 year low of $0.75 and a 1 year high of $8.53. The company has a market capitalization of $765.81 million, a price-to-earnings ratio of -9.06 and a beta of 0.32. The stock's 50-day moving average price is $5.55 and its 200-day moving average price is $2.96.

Remove Ads

Chimerix (NASDAQ:CMRX - Get Free Report) last posted its earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.01. The company had revenue of $0.06 million for the quarter, compared to analysts' expectations of $0.31 million. As a group, equities research analysts forecast that Chimerix will post -0.99 earnings per share for the current year.

Insider Transactions at Chimerix

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of Chimerix stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the sale, the chief executive officer now owns 609,603 shares of the company's stock, valued at $2,755,405.56. The trade was a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last ninety days, insiders sold 20,760 shares of company stock valued at $91,175. Insiders own 13.10% of the company's stock.

Hedge Funds Weigh In On Chimerix

A number of large investors have recently modified their holdings of the company. Assenagon Asset Management S.A. raised its stake in shares of Chimerix by 154.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company's stock worth $2,846,000 after acquiring an additional 496,823 shares in the last quarter. Rosalind Advisors Inc. bought a new position in shares of Chimerix during the 4th quarter valued at $10,614,000. Palumbo Wealth Management LLC purchased a new position in Chimerix in the 4th quarter worth $221,000. Valeo Financial Advisors LLC lifted its stake in Chimerix by 78.8% in the fourth quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company's stock worth $509,000 after purchasing an additional 64,420 shares during the last quarter. Finally, Peapod Lane Capital LLC purchased a new stake in Chimerix during the fourth quarter valued at about $2,626,000. 45.42% of the stock is owned by hedge funds and other institutional investors.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.